Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
Florian Castrop, Bernhard Haslinger, Bernhard Hemmer, Dorothea Buck Department of Neurology, Technische Universität München, Munich, Germany Abstract: Multiple sclerosis (MS) is a common neurological disease with increasing incidence and prevalence. Onset of disease is most frequen...
Guardado en:
Autores principales: | Castrop F, Haslinger B, Hemmer B, Buck D |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a102b9304f3a4140a948739e850e1b16 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis
por: Francesco Manfredonia, et al.
Publicado: (2008) -
The role of glatiramer acetate in the early treatment of multiple sclerosis
por: David W Brandes
Publicado: (2010) -
The Multiple Sclerosis Treatment Optimization Program
por: Annette Langer‐Gould, et al.
Publicado: (2021) -
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke C, et al.
Publicado: (2011) -
Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Clemens Warnke, et al.
Publicado: (2009)